{"id":"W4389231707","doi":"10.1182/blood-2023-180766","title":"Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Ven; Minimal residual disease; Lenalidomide; Multiple myeloma; Bortezomib; Dexamethasone; Venetoclax; Gastroenterology; Oncology; Phases of clinical research; Refractory (planetary science); Progressive disease; Bone marrow; Clinical trial; Chemotherapy; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002002668,0.0003507593,0.001118578,0.0002795335,0.0002451784,0.0007359585,0.0004859498,0.0003097414,0.001713958],"category_scores_gemma":[0.0009687564,0.0003035574,0.0009234613,0.0004869096,0.0002842059,0.0004054462,0.0002439256,0.00139581,0.000225726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006809209,"about_ca_system_score_gemma":0.0008732387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004944646,"about_ca_topic_score_gemma":0.002470038,"domain_scores_codex":[0.9993461,0.0003080316,0.00005198871,0.0001099618,0.0001091265,0.00007486097],"domain_scores_gemma":[0.9988343,0.0002743978,0.0004445196,0.0001228983,0.00008255772,0.0002414556],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4674468,0.01247389,0.1930879,0.001252977,0.006756783,0.00027556,0.0004349031,0.00332623,0.07858615,0.0003356606,0.00934263,0.2266805],"study_design_scores_gemma":[0.1862181,0.2721182,0.4839911,0.0001637649,0.006923562,0.002325177,0.0001978962,0.003318907,0.02376462,0.000532399,0.0203467,0.0000995674],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944915,0.002692865,0.0002000388,0.0001737079,0.00002947402,0.0002998805,0.001159403,0.00003243516,0.0009207344],"genre_scores_gemma":[0.9951421,0.0008834683,0.0007394283,0.0002636123,0.00005936305,0.0002272396,0.002220299,0.000008459939,0.0004561876],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002002668,"threshold_uncertainty_score":0.01059127,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03273877375204344,"score_gpt":0.3312713720477828,"score_spread":0.2985325982957394,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}